Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VizionfocusTPE:4771 -0.74%95 EV-to-EBIT is 10.17 as of Sep. 13, 2026, which is 22% below its 10-year median of 13.02. GuruFocus rates TPE:4771 with a GF Score™ of 95/100 and a GF Value™ of NT$261.11 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 474 Medical Devices & Instruments companies, Vizionfocus ranks better than 74.26% on this metric.
The historical rank and industry rank for Vizionfocus's EV-to-EBIT or its related term are showing as below:
TPE:4771'
s EV-to-EBIT Range Over the Past 10 Years
Min: 9.32 Med: 13.02 Max: 48.4
Current: 10.17
During the past 8 years, the highest EV-to-EBIT of Vizionfocus was 48.40. The lowest was 9.32. And the median was 13.02.
TPE:4771's EV-to-EBIT is ranked better than 74.26% of 474
companies
in the Medical Devices & Instruments industry
Industry Median: 18.005
vs TPE:4771: 10.17
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Vizionfocus's Enterprise Value for the quarter that ended in Jun. 2026 was NT$12,705 Mil.
Vizionfocus's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,280 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vizionfocus EV-to-EBIT Related Terms
Vizionfocus EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Vizionfocus's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Vizionfocus's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vizionfocus EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vizionfocus's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Vizionfocus's EV-to-EBIT falls into.
Vizionfocus's current Enterprise Value is NT$13,028 Mil.
Vizionfocus's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,280 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vizionfocus (TPE:4771) has a EV-to-EBIT of 10.17 as of Sep. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vizionfocus and its competitors. This is 22% below median its historical median of 13.02. Over the past decade, Vizionfocus' EV-to-EBIT has ranged from 9.32 to 48.40. According to the industry distribution chart, Vizionfocus ranks #122 out of 474 companies in the Medical Devices & Instruments industry, placing it in the top 25.7%.
Is Vizionfocus' EV-to-EBIT too high?
Vizionfocus' current EV-to-EBIT of 10.17 is 22% below median its 10-year median of 13.02. Over the past 10 years, this metric has ranged from a low of 9.32 to a high of 48.40. The Medical Devices & Instruments industry median EV-to-EBIT is 18.01. Vizionfocus' value of 10.17 is 43.5% below this industry median. Based on the distribution chart, Vizionfocus ranks #122 out of 474 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Vizionfocus has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vizionfocus' EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Vizionfocus ranks #122 out of 474 companies for EV-to-EBIT. This puts Vizionfocus in the upper half of its industry. The industry median EV-to-EBIT is 18.01. Vizionfocus' value of 10.17 is 43.5% below this benchmark. Historically, Vizionfocus' own EV-to-EBIT has ranged from 9.32 to 48.40 over the past decade. While the company's 10-year median is 13.02 vs. the industry median of 18.01, Vizionfocus has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.01, based on 474 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vizionfocus's current EV-to-EBIT of 10.17 is 43.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vizionfocus and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vizionfocus's current EV-to-EBIT is 10.17, which is 22% below median its own 10-year median of 13.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vizionfocus stock overvalued right now?
Based on GuruFocus' analysis, Vizionfocus (TPE:4771) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$261.11, compared to a current price of NT$201.50 — trading 22.8% below its estimated fair value. The current EV-to-EBIT is 10.17, which is 22% below median its 10-year median of 13.02 and 43.5% below the Medical Devices & Instruments industry median of 18.01. Vizionfocus' overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Vizionfocus (TPE:4771), the current EV-to-EBIT is 10.17 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vizionfocus (TPE:4771) Overvalued in 2026?
Based on GuruFocus' analysis, Vizionfocus stock appears to be undervalued.
The current stock price of NT$201.50 is trading 22.8% below its estimated GF Value™ of NT$261.11.
GuruFocus considers Vizionfocus to be Modestly Undervalued.
Key valuation signals for TPE:4771:
EV-to-EBIT: 10.17 (22% below median its 10-year median of 13.02)
GF Value™: NT$261.11 vs. price of NT$201.50 (22.8% below fair value)
Industry Position: 43.5% below the Medical Devices & Instruments median (#122 of 474)
No single metric tells the full story. See the TPE:4771 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vizionfocus Inc is mainly engaged in the manufacturing of medical equipment, machinery and equipment, optical instruments, precision instruments, international trading, and other consulting services. The Company operates through the VIZIONFOCUS segment, which generates maximum revenue and is engaged in the manufacturing of medical equipment, machinery and equipment, optical instruments, precision instruments, international trading, and other consulting services, and the Jiangsu Vizionfocus Inc. segment, whose main business includes the research and development, design, and production of contact lenses, as well as the wholesale, import, and export of related products.
95GF Score
Get the complete analysis for TPE:4771
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4771 has been successfully added to your 
